About this trial
Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults over 18 years.
Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie.
Group 1: patients with septic shock defined by sepsis with 2 mmol/l Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T°>38.3) with a documented or suspected infection
Group 2: patients with a shock defined by arterial hypotension requiring the use of vasopressors with 2 mmol/l Lactates but without suspected infection and apyrexie (T°<38°). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock
Disqualifiers
Pregnant women
Group 1 : No evidence of suspected or documented infection
Group 2 : Presence of fever and/or suspected infection
Trial design
Parallel
Treatments tested in this trial
blood sample
Biological/Vaccineblood sample in order to measure the concentrations of circulating Vasn
Treatment groups
Trial outcomes
Primary outcomes
Vasn plasma concentration at D0 for each group
Vasn plasma concentration in each group
Vasn plasma concentration in each group
Correlation between Vasn plasma concentration and noradrenaline dose peak in each group
Sponsors and contacts
Click on the lead sponsor to view all of their trials.